Concert Pharmaceuticals asserted that the U.S FDA has offered Fast Track designation for CTP-543, inhibitor for treatment of moderate-to severe Alopecia Areata discerned as a serious autoimmune disorder in which the immune system attacks hair follicles thereby leading to patchy or complete hair loss.
A designation implied to facilitate and aggravate the development to assess new suggestions for treatment of serious conditions. Fast track designation enables effective communications between the FDA and the sponsor throughout the development of drug ensuring sorting out of issues at its earliest.
James Cassella, Ph.D., Chief Development Officer of Concert Pharmaceuticals said “There are no FDA-approved treatments for alopecia areata and CTP-543 would represent a significant medical advance as a potential first-in-class treatment for moderate-to-severe disease.”